Previous 10 | Next 10 |
2023-08-09 17:52:25 ET Equillium press release ( NASDAQ: EQ ): Q2 GAAP EPS of -$0.10 beats by $0.06 . Revenue of $9.12M beats by $2.98M . For further details see: Equillium GAAP EPS of -$0.10 beats by $0.06, revenue of $9.12M beats by $2.98M
$48.4 million in cash at the end of Q2 2023 expected to provide operating runway into 2025 Fully prepaid and retired debt facility Authorized $7.5 million stock repurchase program Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep...
2023-08-02 18:17:24 ET Clinical-stage biotech Equillium ( NASDAQ: EQ ) on Thursday said its board had approved a share buyback of up to $7.5M. EQ stock soared 32% to $0.99 after hours. "This repurchase program does not meaningfully affect our cash runway which remains ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that its Board of Directors authorized the repurchase of up to $7.5 million ...
2023-06-13 16:47:38 ET Equity Commonwealth's ( NYSE: EQC ) board on Tuesday authorized the office property REIT to repurchase up to $150M of its shares outstanding under a new stock buyback program. EQC stock gained 2.5% in Tuesday after-hours trading. The company'...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Inv...
Continued Progress on Recurring Revenue, Increased Gross Margin and a Focus on Profitability TORONTO, ON / ACCESSWIRE / May 19, 2023 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in geospatial data and artificial intelligence driven software and solutions, announced its financi...
EQ102 selectively blocks IL-15 and IL-21 signaling while preserving signaling of other gamma chain family members Data suggest that selective blockade of IL-15 and IL-21 inhibits the synergistic signaling that mediates NK and T cell responses in multiple immune disorders including celiac ...
2023-05-12 16:15:31 ET Summary EQ sold option to purchase rights for Itolizumab to Ono Pharmaceutical: $26M upfront + program reimbursement + $37M if Ono exercises option right (~Q4 2024). Company now focused on 2 multi-cytokine inhibitor programs: alopecia areata (hair loss from ...
2023-05-11 17:42:48 ET Equillium press release ( NASDAQ: EQ ): Q1 GAAP EPS of -$0.11 beats by $0.07 . Revenue of $8.9M. Research and development (R&D) expenses for the first quarter of 2023 were $9.3 million, compared with $10.8 million for the same period in 2...
News, Short Squeeze, Breakout and More Instantly...
Equillium Inc. Company Name:
EQ Stock Symbol:
NASDAQ Market:
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 115.1% to $0.5667 on volume of 77,631,052 shares MicroAlgo Inc. (MLGO) rose 284.0% to $5.99 on volume of 40,752,997 shares Crown Electrokinetics Corp. (CRKN) fell 13.8% to $0.1016 on volume of 28,247,104 sha...